Can Oral Gildeuretinol Slow Advanced Macular Degeneration? - Takeaways - MDSpire

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.

  • By

  • Andrea Surnit

  • July 20, 2026

  • 3 min

Share

  • 1

    Oral gildeuretinol acetate did not significantly slow geographic atrophy progression compared to placebo in age-related macular degeneration patients.

  • 2

    The phase 2/3 SAGA trial involved 198 patients aged 60 and older, assigned to receive either gildeuretinol or placebo for 24 months.

  • 3

    Geographic atrophy lesion growth was reduced by 13% with gildeuretinol, but this difference was not statistically significant.

  • 4

    Secondary outcomes showed exploratory benefits for gildeuretinol, including less decline in low-luminance visual acuity and improved quality of life.

  • 5

    The study's primary endpoint was not met, and researchers emphasized that secondary findings are exploratory and require further investigation.

Original Source(s)

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

  • by Andrea Surnit

  • July 20, 2026

Related Content

Single-cell transcriptomic profiling uncovers pathogenic cellular diversity and potential inflammatory markers in the retinas of STZ-induced diabetic mice

Myopia Severity Tied to Pediatric Retinal Pathology

Routine dilated examinations identified peripheral retinal abnormalities across refractive groups, with higher pathology rates among patients with at least 3.00 D of myopia

Performance of Deep Learning in Classifying Age-Related Macular Degeneration From Images: Systematic Review and Meta-Analysis